Tyme Technologies, Inc. announced efficacy and safety data for SM-88 in patients with advanced metastatic or recurrent pancreatic cancer. The data were presented in a poster presentation at the 2018 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco, Calif. Data from 10 pancreatic cancer patients treated with SM-88 in Tyme’s First Human Study or compassionate use program were evaluated for overall survival, overall response rate, progression-free survival, Eastern Cooperative Oncology Group (ECOG) performance status and pain scores. Many evaluable patients demonstrated prolonged survival with 40% (4/10) surviving more than 12 months, and 30% (3/10) achieving a complete or partial response. All subjects (10/10) reduced or maintained pain scores during their first cycle of SM-88 therapy, in addition to gaining or maintaining weight. 80% (8/10) of patients showed improvement in ECOG performance status during the first treatment cycle, with 30% (3/10) demonstrating an improvement of greater than one point during this six week period. All patients improved or maintained European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire subject-reported health and quality of life outcomes after initiating SM-88 therapy. SM-88 is a novel combination therapy that utilizes a proprietary dysfunctional tyrosine derivative to interrupt the metabolic processes of cancer cells, breaking down the cells’ key defenses and making them vulnerable to oxidative stress and death. SM-88 has demonstrated efficacy in the treatment of multiple oncology indications, including breast and prostate cancer, without reports of significant toxicity or serious adverse events.